BioSpace News Archive

CareDx, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported fourth quarter and full year 2021 financial results and corporate updates.

Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced financial results for the three months and year ended December 31, 2021.

AbCellera, a technology company with a centralized operating system for next-generation antibody discovery, announced financial results for full year 2021.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights.

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd Annual Cowen Health Care Conference.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET.

BD, a leading global medical technology company, announced that it will virtually present at the Cowen 42nd Annual Health Care Conference via webcast.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced recent company highlights and financial results from the fourth quarter and full year ended December 31, 2021.

AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment of amyotrophic lateral sclerosis (ALS) in Canada under the NOC/c procedure and to provide an update on its clinical program in all indications.